Key facts
- This page summarizes John A. Stalfort III's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jun 2026, 16:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Footnote F2
The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
Footnote F3
The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.